Pediatric metabolic dysfunction-associated steatotic liver disease and the gut microbiome: from research landscape to targeted modulation [0.03%]
儿童代谢失衡相关脂肪性肝病与肠道微生态:从研究现状到靶向调节
Lu Jiang,Lan-Duoduo Du,Jing Zeng et al.
Lu Jiang et al.
Metabolic dysfunction-associated steatotic liver disease (MASLD), formally known as non-alcoholic fatty liver disease, has become the most common form of chronic liver disease in children. The spectrum of pediatric MASLD ranges from simple ...
Reply: Methodological Concerns Regarding GLP-1RA Effects on MASLD Outcomes [0.03%]
致编辑:关于GLP-1受体激动剂对MASLD结局影响的方法学担忧回复
Xianhua Mao,Mindie H Nguyen
Xianhua Mao
Beyond Diagnostic Accuracy: Economic and Clinical Considerations for NC-MRI in Late HCC Recurrence Surveillance [0.03%]
超越诊断准确性:晚期HCC复发监测中NC-MRI的经济和临床考量
Qi-Feng Chen,Sui-Xing Zhong,Ming Zhao
Qi-Feng Chen
Hepatocytic ASB3 deficiency alleviates MASLD by decreasing ubiquitin-mediated CPT1A [0.03%]
ASB3肝细胞缺乏通过减少泛素介导的CPT1A降低MASLD
Yuli Lin,Wulei Hou,Mengxiao Ge et al.
Yuli Lin et al.
Background: Excessive lipid accumulation in hepatocytes is a critical cause of metabolic dysfunction-associated steatotic liver disease (MASLD) progression. Ankyrin repeat and SOCS box protein 3 (ASB3) is an E3 ubiquitin ...
Comment on "High Steatosis-Associated Fibrosis Estimator Scores Predict Hepatocellular Carcinoma in Viral and Non-Viral Hepatitis and Metabolic Dysfunction-Associated Steatotic Liver Disease" [0.03%]
关于“高脂肪变性相关纤维化评分能预测病毒性和非病毒性肝炎以及代谢功能异常相关脂肪肝疾病的肝细胞癌”的评论
Prajnasini Satapathy,Rachana Mehta,Ranjana Sah
Prajnasini Satapathy
An editorial on "Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation" by Hong et al [0.03%]
胡宏等关于肝硬化失代偿期患者人巨细胞病毒再激活的述评
Norihiro Imai
Norihiro Imai
Metabolic dysfunction-associated steatotic liver disease(MALSD): On track to become the dominant etiology of hepatocellular carcinoma [0.03%]
与代谢失调相关的肝脂肪变性性疾病(MALSD):将成为肝细胞癌的主要病因
Jian Xu,Wei Zhang,Guo Wu et al.
Jian Xu et al.
Prospects of Late-Stage Development Agents in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) [0.03%]
晚期候选药物治疗代谢紊乱相关肝炎的前景
Brian Lee,Ussama Ghumman,Lisa D Pedicone et al.
Brian Lee et al.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a spectrum of pathology involving fatty liver disease that may progress to fibrosis, cirrhosis, hepatocellular carcinoma, and liver failure. The prevalence of MASLD and met...